Diabetic Peripheral Neuropathic Pain Study
Thursday, June 18, 2009
By: Neuropathy Association
CNS Healthcare is conducting a phase II study for patients in the Orlando, Florida area with diabetic peripheral neuropathic pain. This study is designed to evaluate the safety and efficacy of RGH-896 in patients with diabetic peripheral neuropathic pain.

Transthyretin-Associated Amyloidoses Outcomes Survey (THAOS)
Tuesday, February 17, 2009
By: TNA
THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin-associated amyloidoses (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy), and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate. The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease. A large and diverse data set will maximize the information yield; and for this reason, ATTR patients and their physicians are strongly encouraged to consider participation.

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension
Friday, October 31, 2008
By: TNA
Chelsea Therapeutics is currently recruiting patients for two pivotal phase III trials designed to demonstrate efficacy and support U.S. marketing approval of the orphan drug droxidopa in symptomatic Neurogenic Orthostatic Hypotension (NOH). This double-blind, placebo-controlled study will measure the efficacy of droxidopa on symptoms of orthostatic hypotension in patients with primary autonomic failure (Parkinson's Disease, Multiple System Atrophy, Pure Autonomic Failure), dopamine beta hydroxylane deficiency and non-diabetic neuropathy. A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing is also an inclusion criteria. The study will be a maximum of 7 weeks.

High Dose Ascorbic Acid Treatment of CMT1A
Wednesday, September 12, 2007
By: TNA
The purpose of the study is to evaluate whether high doses of ascorbic acid have any effect on Charcot-Marie-Tooth disease type 1A (CMT1A) and whether or not it should be studied further. Ascorbic acid is also known as vitamin C and has been used and studied extensively for other purposes, but it has never been used to try to treat CMT1A.